• Home
  1. Home
  2. Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial
Scientific article
English

Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial

ContributorsHess, Viviane; Salzberg, Marc; Borner, Markus; Morant, Rudolf; Roth, Arnaud; Ludwig, Christian; Herrmann, Richard
Published inJournal of clinical oncology, vol. 21, no. 1, p. 66-68
Publication date2003
Abstract

Preclinical studies indicate positive interactions between capecitabine, an oral fluorouracil precursor, and gemcitabine, the current standard treatment for advanced pancreatic carcinoma (APC). In this study, we investigated the addition of capecitabine to gemcitabine treatment for patients with APC.

Keywords
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use
  • Deoxycytidine/administration & dosage/adverse effects/analogs & derivatives
  • Female
  • Fluorouracil/analogs & derivatives
  • Humans
  • Male
  • Maximum Tolerated Dose
  • Middle Aged
  • Pancreatic Neoplasms/drug therapy/mortality
  • Survival Rate
  • Switzerland/epidemiology
Affiliation entities
Research groups
Citation (ISO format)
HESS, Viviane et al. Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial. In: Journal of clinical oncology, 2003, vol. 21, n° 1, p. 66–68. doi: 10.1200/JCO.2003.04.029
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
Additional URL for this publicationhttp://jco.ascopubs.org/content/21/1/66.long
Journal ISSN0732-183X
521views
0downloads

Technical informations

Creation13/01/2015 13:04:00
First validation13/01/2015 13:04:00
Update12/03/2026 10:47:17
Status update12/03/2026 10:47:17
Last indexation12/03/2026 10:53:07
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack